Abivax (NASDAQ:ABVX - Free Report) had its price target raised by Lifesci Capital from $45.00 to $101.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an outperform rating on the stock. Lifesci Capital also issued estimates for Abivax's FY2025 earnings at ($3.64) EPS.
Other equities analysts have also issued research reports about the company. Piper Sandler increased their target price on Abivax from $42.00 to $70.00 and gave the company an "overweight" rating in a report on Wednesday. Citigroup reissued a "market outperform" rating on shares of Abivax in a report on Friday, July 18th. JMP Securities increased their target price on Abivax from $33.00 to $95.00 and gave the company a "market outperform" rating in a report on Wednesday. Guggenheim raised their price objective on Abivax from $50.00 to $101.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, Leerink Partners set a $74.00 price objective on Abivax and gave the stock an "outperform" rating in a report on Wednesday. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $80.00.
Read Our Latest Report on Abivax
Abivax Price Performance
NASDAQ ABVX traded down $3.27 during trading hours on Wednesday, hitting $66.49. 3,538,569 shares of the company were exchanged, compared to its average volume of 2,638,802. The company has a 50 day moving average of $11.03 and a two-hundred day moving average of $8.13. The company has a debt-to-equity ratio of 1.29, a current ratio of 1.25 and a quick ratio of 1.25. Abivax has a 52-week low of $4.77 and a 52-week high of $72.90.
Institutional Investors Weigh In On Abivax
Hedge funds have recently made changes to their positions in the company. Bank of America Corp DE lifted its position in Abivax by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock worth $41,000 after buying an additional 1,990 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in shares of Abivax by 34.3% during the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company's stock worth $63,000 after purchasing an additional 2,595 shares during the last quarter. Ameriprise Financial Inc. acquired a new position in shares of Abivax during the 4th quarter worth $85,000. Guggenheim Capital LLC acquired a new position in shares of Abivax during the 4th quarter worth $92,000. Finally, Stonepine Capital Management LLC acquired a new position in shares of Abivax during the 4th quarter worth $110,000. Hedge funds and other institutional investors own 47.91% of the company's stock.
About Abivax
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Featured Articles
Before you consider Abivax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.
While Abivax currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
